Methylin (Methylphenidate Hydrochloride) - Indications and Dosage

INDICATIONS AND USAGE

Attention Deficit Disorders, Narcolepsy

Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.

Methylin is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Special Diagnostic Considerations

Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources.

Characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate-to-severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.

Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.

DOSAGE AND ADMINISTRATION

Dosage should be individualized according to the needs and responses of the patient.

Adults

Tablets: Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Some patients may require 40 to 60 mg daily. In others, 10 to 15 mg daily will be adequate. Patients who are unable to sleep if medication is taken late in the day should take the last dose before 6 p.m.

ER Tablets: Methylin ER tablets have a duration of action of approximately 8 hours. Therefore, Methylin ER tablets may be used in place of Methylin tablets when the 8-hour dosage of Methylin ER corresponds to the titrated 8-hour dosage of Methylin. Methylin ER tablets must be swallowed whole and never crushed or chewed.

Children (6 years and over)

Methylin should be initiated in small doses, with gradual weekly increments. Daily dosage above 60 mg is not recommended.

If improvement is not observed after appropriate dosage adjustment over a one-month period, the drug should be discontinued.

Tablets: Start with 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly.

ER Tablets: Methylin ER tablets have a duration of action of approximately 8 hours. Therefore, Methylin ER tablets may be used in place of Methylin tablets when the 8-hour dosage of Methylin ER corresponds to the titrated 8-hour dosage of Methylin. Methylin ER tablets must be swallowed whole and never crushed or chewed.

If paradoxical aggravation of symptoms or other adverse effects occur, reduce dosage, or, if necessary, discontinue the drug.

Methylin should be periodically discontinued to assess the child's condition. Improvement may be sustained when the drug is either temporarily or permanently discontinued.

Drug treatment should not and need not be indefinite and usually may be discontinued after puberty.

HOW SUPPLIED

Each Methylin^® (methylphenidate HCl tablet USP) 5 mg is available as a round, white unscored tablet debossed with 5 on one side and a

•  Bottles of 100........................NDC 0406-1121-01
•  Bottles of 1000......................NDC 0406-1121-10

Each Methylin^® (methylphenidate HCl tablet USP) 10 mg is available as a round, white scored tablet debossed with 10 on one side of the tablet and a M on the other side.

•  Bottles of 100........................NDC 0406-1122-01
•  Bottles of 1000......................NDC 0406-1122-10

Each Methylin^® (methylphenidate HCl tablet USP) 20 mg is available as a round, white scored tablet debossed with 20 on one side of the tablet and a

•  Bottles of 100........................NDC 0406-1124-01
•  Bottles of 1000......................NDC 0406-1124-10

Protect from light. Dispense in tight, light-resistant container with child-resistant closure.

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Each Methylin^® ER (methylphenidate HCl extended-release tablet USP) 10 mg is available as a round, white to off-white tablet, debossed with 1423 on one side and a

•  Bottles of 100........................NDC 0406-1423-01

Each Methylin^® ER (methylphenidate HCl extended-release tablet USP) 20 mg is available as a round, white to off-white tablet, debossed with 1451 on one side and a

•  Bottles of 100........................NDC 0406-1451-01

Note: Methylin^® and Methylin^® ER tablets are color-additive free.

Dispense in tight, light-resistant container with child-resistant closure.

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from moisture.

Methylin^® is a registered trademark of Mallinckrodt Inc.

Mallinckrodt Inc.
St. Louis, MO 63134 U.S.A.

tyco
Healthcare
Mallinckrodt

Printed in U.S.A.
Rev 041807